Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT), including opioid treatment programs (OTPs), combines behavioral therapy and medications to treat substance use disorders.

CARA ACT: Request for Public Comment on New Buprenorphine Training Requirements

On October 1st, 2016, SAMHSA held a public meeting to solicit feedback on the Comprehensive Addiction Recovery Act (CARA) of 2016 nurse practitioner and physician assistant training requirements. (See 81 FR 63780.) Comments for SAMHSA consideration may be submitted to till November 1, 2016.

To prescribe or dispense buprenorphine, physicians must qualify and apply for a waiver under the Drug Addiction Treatment Act of 2000 (DATA 2000).

Physicians can complete the Online Request for Patient Limit Increase.

Physicians are also required to complete buprenorphine training.

Learn more about how to:

Physicians can join the SAMHSA Buprenorphine Clinical Discussion WebBoard to ask and discuss questions on the clinical use of buprenorphine.

A combination of medication and counseling and behavioral therapy is effective in treating alcohol and opioid dependency.

Find information on physical ailments often diagnosed in MAT patients. Also known as common comorbidities, these include viral hepatitis, HIV, and AIDS.

Last Updated: 10/17/2016